Your browser is no longer supported. Please, upgrade your browser.
BPMX BioPharmX Corporation daily Stock Chart
BioPharmX Corporation
Index- P/E- EPS (ttm)-2.02 Insider Own0.70% Shs Outstand11.19M Perf Week3.01%
Market Cap9.91M Forward P/E- EPS next Y-1.32 Insider Trans- Shs Float10.51M Perf Month5.12%
Income-16.50M PEG- EPS next Q-0.31 Inst Own18.70% Short Float4.97% Perf Quarter-63.93%
Sales0.04M P/S254.07 EPS this Y14.50% Inst Trans0.67% Short Ratio0.82 Perf Half Y-64.97%
Book/sh0.15 P/B5.90 EPS next Y0.00% ROA-334.10% Target Price5.63 Perf Year-84.40%
Cash/sh0.29 P/C3.00 EPS next 5Y- ROE-870.10% 52W Range0.81 - 6.75 Perf YTD-67.17%
Dividend- P/FCF- EPS past 5Y35.40% ROI- 52W High-86.88% Beta0.49
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low9.32% ATR0.07
Employees20 Current Ratio1.40 Sales Q/Q- Oper. Margin- RSI (14)35.96 Volatility7.60% 6.87%
OptionableNo Debt/Eq0.00 EPS Q/Q37.30% Profit Margin- Rel Volume1.06 Prev Close0.89
ShortableYes LT Debt/Eq0.00 EarningsJun 20 AMC Payout- Avg Volume636.39K Price0.89
Recom- SMA202.74% SMA50-26.48% SMA200-69.47% Volume674,626 Change-0.91%
Sep-13-17Reiterated Maxim Group Buy $3 → $1.50
Apr-15-16Initiated Maxim Group Buy $3
Apr-07-16Initiated H.C. Wainwright Buy $3
Sep-04-15Initiated Sterne Agee CRT Buy
Jun-11-19 04:10PM  BioPharmX Reports Fiscal First Quarter 2020 Financial Results PR Newswire
May-22-19 08:10AM  BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea PR Newswire -7.99%
Apr-26-19 07:30AM  BioPharmX Completes 1-for-25 Reverse Stock Split PR Newswire -23.57%
Apr-15-19 04:15PM  BioPharmX Announces Reverse Stock Split PR Newswire
Mar-21-19 08:55AM  BioPharmX Announces $3.9 Million Offering PR Newswire -20.67%
Mar-19-19 02:30PM  Watch These Four Healthcare Stocks Set The Pace On Tuesday ACCESSWIRE +22.87%
Mar-18-19 06:45AM  BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference PR Newswire +14.01%
Mar-14-19 04:05PM  BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results PR Newswire
Mar-13-19 09:30AM  Can We See Significant Institutional Ownership On The BioPharmX Corporation (NYSEMKT:BPMX) Share Register? Simply Wall St.
Mar-04-19 06:00AM  BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea PR Newswire +8.63%
Feb-28-19 01:45PM  These Four Tech Stocks Could Test February Highs ACCESSWIRE
Feb-27-19 04:15PM  BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American PR Newswire
Feb-04-19 07:00AM  BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott PR Newswire
Jan-29-19 08:10AM  Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX Future Expectations, Projections Moving into 2019 GlobeNewswire
Jan-09-19 07:00AM  Market Rally Extends to Biotech ACCESSWIRE -9.17%
Dec-20-18 04:30PM  BioPharmX Receives Notice of Noncompliance from NYSE American PR Newswire -7.25%
Dec-06-18 04:10PM  BioPharmX Reports Third Quarter 2019 Financial Results PR Newswire
Dec-05-18 06:19AM  Is BioPharmX Corporations (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Nov-16-18 06:00AM  BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance PR Newswire
Oct-23-18 07:55AM  Report: Exploring Fundamental Drivers Behind Helen of Troy, BioPharmX, Fair Isaac, Frontier Communications, ICU Medical, and Darling Ingredients New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-11-18 04:30PM  BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea PR Newswire
Sep-28-18 09:15AM  BioPharmX Receives Notice of Noncompliance from NYSE American PR Newswire -9.91%
Sep-14-18 07:30AM  Who Are The Major Shareholders In BioPharmX Corporation (NYSEMKT:BPMX)? Simply Wall St. -8.10%
Sep-12-18 05:30PM  BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer PR Newswire -8.72%
08:00AM  Todays Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX ACCESSWIRE
Aug-30-18 04:15PM  BioPharmX Reports Second Quarter 2019 Financial Results PR Newswire
Aug-28-18 07:55AM  Detailed Research: Economic Perspectives on Allegheny Technologies, Ring Energy, Aerohive Networks, Omeros, Adtalem Global Education, and BioPharmX What Drives Growth in Today's Competitive Landscape GlobeNewswire
Aug-14-18 06:00PM  BioPharmX Announces Results of Annual Shareholders Meeting PR Newswire
Aug-09-18 06:15AM  BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage Forms PR Newswire
Jul-31-18 09:15AM  BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea PR Newswire
Jul-26-18 08:00AM  Free Technical Insights on BioPharmX and Three Other Biotech Stocks ACCESSWIRE
Jul-20-18 08:05AM  Todays Research Reports on Stocks to Watch: MiMedx Group and BiopharmX ACCESSWIRE
Jul-19-18 11:17AM  3 Biotech Stocks to Watch This Quarter ACCESSWIRE +16.06%
09:15AM  BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01 PR Newswire
Jun-27-18 08:15AM  Report: Developing Opportunities within Valvoline, Parker Drilling, Dean Foods, BioPharmX, Hasbro, and Alnylam Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire -10.15%
Jun-19-18 09:15AM  New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatology PR Newswire -5.70%
07:30AM  Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent -Thalassemia ACCESSWIRE
07:00AM  Free Technical Research on BioPharmX and Three More Biotech Equities bio ACCESSWIRE
Jun-07-18 04:15PM  BioPharmX Reports First Quarter 2019 Financial Results PR Newswire
10:30AM  BioPharmX Displays Progress in BPX-01 and BPX-04 Clinicals, Pipeline Review and Target ACCESSWIRE
May-24-18 09:00AM  BioPharmX Studies Show Hydrophilic Topical Minocycline Gels May Be the Preferred Treatment Option for Acne, Rosacea Patients PR Newswire
May-15-18 12:11PM  BioPharmX Corporation (NYSEMKT:BPMX): What Does The Future Look Like? Simply Wall St.
May-10-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within Energy Transfer Equity, Mednax, BioPharmX, Owens & Minor, SunPower, and Convergys New Research Emphasizes Economic Growth GlobeNewswire
Apr-27-18 11:06AM  Why BioPharmX Corporations (NYSEMKT:BPMX) Investor Composition Impacts Your Returns Simply Wall St.
Apr-26-18 04:15PM  BioPharmX Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Mar-21-18 08:00AM  Todays Research Reports on Trending Tickers: BioPharmX and MediWound ACCESSWIRE
Mar-20-18 08:30PM  BioPharmX Cancels Presentation at Oppenheimer's 28th Annual Healthcare Conference Due to Severe Weather PR Newswire +17.55%
09:15AM  U.S. Patent and Trademark Office Awards BioPharmX Patent Protection for Novel Tetracycline-class Topical Drug Compositions PR Newswire
Mar-14-18 09:15AM  BioPharmX to Present at Oppenheimer's 28th Annual Healthcare Conference PR Newswire -5.11%
Mar-07-18 01:39PM  Loss-Making BioPharmX Corporation (NYSEMKT:BPMX) Expected To Breakeven Simply Wall St.
Mar-05-18 09:15AM  BioPharmX to Present at 30th Annual ROTH Conference PR Newswire +6.20%
Feb-07-18 08:15AM  Investor Expectations to Drive Momentum within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX Discovering Underlying Factors of Influence GlobeNewswire -11.75%
Jan-26-18 09:15AM  BioPharmX To Present Data On New Fluorescence Lifetime Imaging Microscopy to Measure How Effectively Topically Applied Minocycline Reaches Targets in Skin PR Newswire
Jan-12-18 09:15AM  BioPharmX To Present BPX-04 Rosacea Data At Two Leading Clinical Conferences This Month PR Newswire
Jan-09-18 07:40AM  Free Post Earnings Research Report: BioPharmXs Adjusted EPS Beat Expectations ACCESSWIRE +8.76%
Dec-25-17 05:35PM  How Do Analysts See BioPharmX Corporation (NYSEMKT:BPMX) Performing In The Years Ahead? Simply Wall St.
Dec-15-17 08:05PM  How BioPharmX Corporations (NYSEMKT:BPMX) EPS Growth Stacks Up Against Industry Performance Simply Wall St.
07:10AM  Blog Exposure - MabVax Therapeutics Completes Enrollment and Dosing In Initial Cohort of Phase-1 Trial of Its Cancer Drug MVT-1075 ACCESSWIRE
Dec-14-17 12:58PM  ETFs with exposure to BioPharmX Corp. : December 14, 2017 Capital Cube
Dec-13-17 10:14AM  BioPharmX Corp. :BPMX-US: Earnings Analysis: Q3, 2018 By the Numbers : December 13, 2017 Capital Cube
Dec-07-17 04:15PM  BioPharmX Reports Third Quarter 2018 Financial Results PR Newswire
Dec-04-17 09:15AM  BioPharmX Demonstrates Topical Minocycline Gel May Exhibit Relevant Antimicrobial and Anti-inflammatory Properties for the Treatment of Acne at ASCB 2017 PR Newswire
Dec-01-17 10:30AM  ETFs with exposure to BioPharmX Corp. : December 1, 2017 Capital Cube -6.96%
Nov-21-17 09:05AM  BioPharmX Corporation Announces Pricing of Public Offering PR Newswire -32.76%
Nov-16-17 08:20AM  Report: Developing Opportunities within Graphic Packaging Holding, Invitation Home, Teradyne, Dean Foods, Valley National, and BioPharmX Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-13-17 12:55PM  Should You Be Concerned About BioPharmX Corporations (BPMX) Shareholders? Simply Wall St. +5.48%
Nov-08-17 09:15AM  BioPharmX Receives Concurrence from FDA on Phase 3 Acne Study Plans PR Newswire +15.84%
Nov-07-17 09:49AM  ETFs with exposure to BioPharmX Corp. : November 7, 2017 Capital Cube +22.24%
Oct-18-17 10:30AM  BioPharmX to Present at Re-entering Antibacterial Discovery and Development Summit 2017 PR Newswire
Oct-11-17 10:30AM  BioPharmX Collaborates with Wellman Center for Photomedicine to Develop Pioneering, Cost-Effective Technique to Visualize Drug Delivery PR Newswire
Oct-10-17 11:04AM  ETFs with exposure to BioPharmX Corp. : October 10, 2017 Capital Cube
Sep-28-17 11:50AM  Is BioPharmX Corporation (BPMX) Still A Cheap Healthcare Stock? Simply Wall St. -5.78%
Sep-26-17 10:44AM  ETFs with exposure to BioPharmX Corp. : September 26, 2017 Capital Cube +16.18%
Sep-25-17 07:00AM  Earnings Review and Free Research Report: Can-Fites Revenue Increased 25% ACCESSWIRE -5.00%
Sep-15-17 05:15PM  ETFs with exposure to BioPharmX Corp. : September 15, 2017 Capital Cube +6.09%
Sep-14-17 02:21PM  BioPharmX Corp. :BPMX-US: Earnings Analysis: Q2, 2018 By the Numbers : September 14, 2017 Capital Cube
Sep-13-17 09:00AM  BioPharmX Reports Second Quarter 2018 Financial Results PR Newswire -11.76%
Sep-12-17 07:30AM  BioPharmX Announces Preliminary Data from Rosacea Feasibility Study PR Newswire
Sep-05-17 09:15AM  BioPharmX to Present at Rodman & Renshaw 19th Annual Global Investment Conference PR Newswire +6.11%
Jul-27-17 09:15AM  Summer AAD Panel to Discuss BPX-01 for Acne and Rosacea PR Newswire
Jul-13-17 09:15AM  BioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017 PR Newswire
Jul-12-17 02:16PM  ETFs with exposure to BioPharmX Corp. : July 12, 2017 Capital Cube
Jun-26-17 08:15AM  Corporate News Blog - Repligen Corp. and Spectrum Merge to Form Leader in Filtration for Bioprocessing Industry Accesswire
Jun-22-17 09:15AM  BioPharmX to Present Phase 2b Clinical Trial Acne Data at Alabama Dermatology Society Summer Symposium PR Newswire +7.70%
Jun-19-17 03:01PM  ETFs with exposure to BioPharmX Corp. : June 19, 2017 Capital Cube
Jun-16-17 11:01AM  BioPharmX Corp. :BPMX-US: Earnings Analysis: Q1, 2018 By the Numbers : June 16, 2017 Capital Cube
Jun-14-17 09:00AM  BioPharmX Invited to Present at World Preclinical Congress PR Newswire
Jun-13-17 04:05PM  BioPharmX Reports First Quarter 2018 Financial Results PR Newswire
Jun-07-17 06:15AM  BioPharmX to Report First Quarter Financial Results PR Newswire
Jun-01-17 08:15AM  BioPharmX Advances BPX-01 2% Upon Achieving Statistical Significance for Primary Endpoint PR Newswire
May-23-17 12:30PM  ETFs with exposure to BioPharmX Corp. : May 23, 2017 Capital Cube
May-11-17 09:25AM  BioPharmX to Host "State of Acne" Symposium on June 1 PR Newswire
May-08-17 04:14PM  ETFs with exposure to BioPharmX Corp. : May 8, 2017 Capital Cube
May-03-17 04:05PM  BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acne PR Newswire
Apr-28-17 04:15PM  BioPharmX Announces Closing of $5.0 Million Offering PR Newswire
Apr-26-17 03:09PM  ETFs with exposure to BioPharmX Corp. : April 26, 2017 Capital Cube
09:00AM  BioPharmX Announces $5.0 Million Offering PR Newswire
Apr-25-17 10:55AM  BioPharmX Corp. :BPMX-US: Earnings Analysis: Q4, 2017 By the Numbers : April 25, 2017 Capital Cube
Apr-20-17 09:15AM  BioPharmX Completes Last Subject Visit in its Phase 2b Trial of BPX-01, Expects to Report Topline Results First Half of May 2017 PR Newswire
Mar-30-17 09:15AM  BioPharmX AACR Poster Will Present Findings Suggesting Molecular Iodine Inhibits Breast Cancer Cell Growth and Drives Cancer Cell Death PR Newswire
BioPharmX Corporation, a specialty pharmaceutical company, develops products for the treatment of dermatologic conditions using its proprietary HyantX topical delivery system. Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb clinical trial for the treatment of inflammatory lesions of acne; and BPX04, a topical antibiotic, which is in Phase IIb study for the treatment of inflammatory lesions of rosacea. The company serves pharmaceutical companies, physician's practices, dermatologists, and general practitioners. BioPharmX Corporation is headquartered in San Jose, California.